5 employees
Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
2021
$7.5M
from 1 investors over 1 rounds
Currus Biologics Pty Ltd raised $7.5M on June 29, 2021
Investors: Uniseed